Insmed Inc
NASDAQ:INSM
Intrinsic Value
Insmed, Inc. is a global biopharmaceutical company, which engages in the development and commercialization of therapies for patients with rare diseases. [ Read More ]
The intrinsic value of one INSM stock under the Base Case scenario is 54.2 USD. Compared to the current market price of 24.92 USD, Insmed Inc is Undervalued by 54%.
Valuation Backtest
Insmed Inc
Run backtest to discover the historical profit from buying and selling INSM stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Insmed Inc
Current Assets | 929.1m |
Cash & Short-Term Investments | 780.4m |
Receivables | 41.2m |
Other Current Assets | 107.4m |
Non-Current Assets | 400.8m |
PP&E | 104.4m |
Intangibles | 199.8m |
Other Non-Current Assets | 96.6m |
Current Liabilities | 225.6m |
Accounts Payable | 68.7m |
Accrued Liabilities | 154.3m |
Other Current Liabilities | 2.6m |
Non-Current Liabilities | 1.4B |
Long-Term Debt | 1.2B |
Other Non-Current Liabilities | 253.8m |
Earnings Waterfall
Insmed Inc
Revenue
|
305.2m
USD
|
Cost of Revenue
|
-65.6m
USD
|
Gross Profit
|
239.6m
USD
|
Operating Expenses
|
-920.6m
USD
|
Operating Income
|
-680.9m
USD
|
Other Expenses
|
-68.6m
USD
|
Net Income
|
-749.6m
USD
|
Free Cash Flow Analysis
Insmed Inc
INSM Profitability Score
Profitability Due Diligence
Insmed Inc's profitability score is 35/100. The higher the profitability score, the more profitable the company is.
Score
Insmed Inc's profitability score is 35/100. The higher the profitability score, the more profitable the company is.
INSM Solvency Score
Solvency Due Diligence
Insmed Inc's solvency score is 41/100. The higher the solvency score, the more solvent the company is.
Score
Insmed Inc's solvency score is 41/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
INSM Price Targets Summary
Insmed Inc
According to Wall Street analysts, the average 1-year price target for INSM is 44.74 USD with a low forecast of 35.35 USD and a high forecast of 57.75 USD.
Ownership
INSM Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
INSM Price
Insmed Inc
Average Annual Return | -7.5% |
Standard Deviation of Annual Returns | 33.15% |
Max Drawdown | -63% |
Market Capitalization | 3.7B USD |
Shares Outstanding | 148 555 008 |
Percentage of Shares Shorted | 6.18% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Insmed, Inc. is a global biopharmaceutical company, which engages in the development and commercialization of therapies for patients with rare diseases. The company is headquartered in Bridgewater, New Jersey and currently employs 613 full-time employees. Its clinical-stage pipeline includes brensocatib and treprostinil palmitil inhalation powder (TPIP). Brensocatib is a small molecule, oral, reversible inhibitor of dipeptidyl peptidase 1, which is developing for the treatment of patients with bronchiectasis, cystic fibrosis (CF) and other neutrophil-mediated diseases, including chronic rhinosinusitis without nasal polyps (CRS) and hidradenitis suppurativa (HS). TPIP is an inhaled formulation of the treprostinil prodrug treprostinil palmitil which may offer a differentiated product profile for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Contact
IPO
Employees
Officers
The intrinsic value of one INSM stock under the Base Case scenario is 54.2 USD.
Compared to the current market price of 24.92 USD, Insmed Inc is Undervalued by 54%.